Therapies with 3rd generation EGFR tyrosine kinase inhibitors
The present invention relates to therapies with 3 rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC).
1. A method of treating cancer in a human subject comprising administering lazertinib to the subject in an amount between about 20 mg and about 320 mg once daily, wherein the cancer is EGFR Mutation Positive non-small cell lung cancer (NSCLC).
2. The method of claim 1 , wherein the cancer is EGFR T790M+ NSCLC.
3. The method of claim 1 , wherein the subject exhibits brain metastasis.
4. The method of claim 1 comprising administering the lazertinib to the subject in an amount between about 40 mg and about 240 mg once daily.
5. The method of claim 1 comprising administering the lazertinib to the subject in an amount of about 240 mg once daily.
6. The method of claim 1 comprising administering the lazertinib to the subject once daily over a period of at least 3 weeks.
7. The method of claim 1 comprising administering the lazertinib to the subject once daily over a period of at least 6 weeks.